Browse our latest Cancer Biology articles

In isogenically matched colorectal cancer (CRC) cell lines, mutant KRAS alters the composition of secreted miRNAs in extracellular vesicles that can then transfer repressive activity to wild type cells.

Co-mutation of two powerful oncogenes in certain cell types may have a lethal effect that explains the mutual exclusivity of the mutations.

The discovery and preclinical validation of a novel gene signature predictive for response to HDM2-targeting drug NVP-CGM097 could significantly improve the clinical response rate to all p53-HDM2 inhibitors.

Increasing the internal pH of cells can induce dysplasia and enhance oncogene-increased cell growth, while decreasing the internal pH combined with oncogene expression leads to synthetic lethality.

SOX2 causes resistance to anti-EGFR therapies in EGFR-mutant lung cancer.

Disrupting extrusion, a process that drives epithelial cell death, leads to increased cell survival, poor barrier function, and enhanced cell invasion and, thereby, promotes tumor initiation and progression.

The oncogenic potential of the serine threonine kinase AKT is not exclusively dependent on catalytic activity, but also involves the non-catalytic function of the pleckstrin homology domain.

Anti-targets are proteins that cause problems when inhibited along with an intended target and our novel chemical strategy affords unprecedented selectivity in the context of FLT3 vs. KIT inhibition for treatment of a devastating blood cancer.

Loss of RUNX1, a key regulator of estrogen receptor-positive luminal breast cells, impairs mammary epithelial differentiation and contributes to luminal breast cancer via genetic interactions with a loss of p53 or RB1.